Meet Lipum at NLSDays in Malmö, Sept 12-14

Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at Nordic Life Science Days 2017 in Malmö.

A novel target molecule

We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases. Lipum has collected original research data proving the efficacy of the compound in several established arthritis models. The BSSL antibodies effectively block human inflammatory cell migration. We are currently developing a humanized monoclonal antibody that target BSSL and our candidate drug will then be subject for toxicological tests and clinical trials. Lipum is actively seeking partners for a faster development or out-licensing of our technology, read more here